Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (REACT): Results of a double-blind randomized phase II trial

for the ReACT trial investigators

Research output: Contribution to journal › Article › peer-review

114 Scopus citations

Fingerprint

Dive into the research topics of 'Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (REACT): Results of a double-blind randomized phase II trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry